<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765114</url>
  </required_header>
  <id_info>
    <org_study_id>DEV-PEG-02</org_study_id>
    <nct_id>NCT01765114</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes</brief_title>
  <official_title>A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Devirex AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Devirex AG</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is therefore to investigate the efficacy of the PEG-formulation to
      reduce the frequency and duration of genital herpes recurrences, to assess its safety and
      tolerability and to investigate its effect on shedding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of number of genital herpes recurrences during the treatment period as compared to the baseline period.</measure>
    <time_frame>Baseline and Treatment period (6 months each).</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of genital herpes recurrences will be counted during the baseline period (6 months) and during the treatment period (6 months) and then be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of the PEG-formulation via reporting of AEs.</measure>
    <time_frame>Baseline and Treatment period (6 months each).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The frequency of days with viral shedding which will be analysed by quantitative PCR.</measure>
    <time_frame>Baseline and Treatment period (6 months each).</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Genital Herpes</condition>
  <arm_group>
    <arm_group_label>PEG-Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Formulation</intervention_name>
    <arm_group_label>PEG-Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent

          -  18 - 65 years

          -  Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)

          -  Initial infection &gt; 1 year ago

          -  ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic
             therapy)

          -  ≥ 2 recurrences during the six-month baseline period

        Exclusion Criteria:

          -  Known or suspected allergy or intolerability to PEG

          -  Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs
             and steroids within less than 14 days prior to baseline period, or plan to take such
             drugs during the trial

          -  Pregnancy and/or breast-feeding

          -  History of malignant diseases (described in chapter 7.2)

          -  Known or suspected non-compliance to study protocol

          -  Participation in another investigational drug study in the last 30 days prior to
             baseline period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kuendig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Kuendig, MD</last_name>
    <phone>+41 (0)44 255 39 73</phone>
    <email>thomas.kuendig@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabian Tay, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>fabian.tay@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Kuendig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 2, 2013</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
